BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

The purpose of this study is to evaluate the safety and efficacy of CM-336, which is a BCMA/CD3 BiTE, in the treatment of high risk smoldering multiple myeloma.

Trial Details

NCT ID
NCT06745687
Phase
NA
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Smoldering Myeloma Multiple Myeloma
Interventions
  • CM336
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Know and voluntarily sign an informed consent form (ICF).
  • Age ≥18 years.
  • Definite diagnosis of SMM: According to IMWG Criteria 10, the patient must have histologically or cytologically confirmed smoldering multiple myelo…
  • Serum M protein ≥3 g /dL and/or BMPCs≥10%(but not more than 60%)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Smoldering Myeloma Multiple Myeloma Trials on Trialify →